Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects
Brief Summary: The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alpha-2a and ribavirin as part of their treatment.


Options:
A: Arm Label: Treatment A: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment B: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment C: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment D: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment E: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment F: PSI-7977 + Daclatasvir+ Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment G: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment H: PSI-7977 + BMS-790052 + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment I: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment J: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: PSI-7977; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment J: PSI-7977 + Daclatasvir + Ribavirin
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207217 | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335 | Arm Label: 8; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 9; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 10; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 11; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 207127, Drug: BI 201335 | Arm Label: 12; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207217; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 10
C: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435
D: Arm Label: Placebo+PEG2b+RBV, x 44 weeks; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, Response Guided Therapy; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, x 44 weeks; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908) | Intervention Type: DRUG; Name: Boceprevir (SCH 503034); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks | Intervention Type: BIOLOGICAL; Name: Pegylated interferon alfa-2b (SCH 54031); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Ribavirin (SCH 18908); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Boceprevir placebo; Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Placebo+PEG2b+RBV, x 44 weeks

Answer: C